alexa Synthesis Of Novel Furan-based Antituberculars Potentially Targeting The Methionine Aminopeptidases (MtMetAP1a)
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

6th World Congress on Medicinal Chemistry and Drug Design
June 07-08, 2017 Milan, Italy

Arianna Gelain, Stefania Villa, Matteo Mori, Laurent R Chiarelli, Luca Costantino, Tiziano Tuccinardi and Fiorella Meneghetti
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Italy
Posters & Accepted Abstracts: Med Chem (Los Angeles)
DOI: 10.4172/2161-0444-C1-031
Abstract
Methionine aminopeptidase (MetAP) carries out an essential function of protein N-terminal processing in many bacteria and is a promising target to develop novel antitubercular agents. MetAP is divided into two subtypes, namely type 1 and type 2. Eukaryotic cells have both subtypes, and prokaryotic cells have only one, which codes for a type 1 MetAP. Mycobacterium tuberculosis has two MetAP genes and both belong to type 1 MetAP: MtMetAP1a and MtMetAP1c, which are essential for its in vivo survival and pathogenicity1. As furan-based compounds have shown to be promising antitubercular agents as MetAPs inhibitors2, we planned the design and synthesis of new derivatives functionalizing 2 and 5 positions of the furane ring (Figure 1), starting from our hit compound, MM40. This latter is the most potent competitive MbtI inhibitor to date identified and exhibited a promising antibiotic activity. MbtI is the salicylate synthase from Mycobacterium tuberculosis which catalyzes the first step in mycobactins biosynthesis, that is a validated target for fighting tuberculosis3. These compounds could be synergically able to act on MetAPs and MbtI, leading to new antituberculars.
Biography

Arianna Gelain graduated in Medicinal Chemistry and Technology and achieved her PhD degree in Medicinal Chemistry at University of Milan. She is researcher at Departement of Pharmaceutical Science and assistant professor at faculty of pharmacy. She is co-author of 31 papers, 6 reviews, published in peer reviewed journals and 1 book chapter.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords